Table 5.

Incidence of various levels of decline in eGFR from values at 6 months postrandomization in the SPRINT participants with CKD

eGFR Reduction from Month 6, %aNo. of Events (% per 1 yr)bIntensive Treatment Versus Standard Treatment
Intensive Treatment, n=1330Standard Treatment, n=1316HR (95% CI)P Value
507 (0.17)4 (0.10)1.65 (0.48 to 5.62)0.42
4015 (0.37)14 (0.36)1.01 (0.49 to 2.10)0.98
3044 (1.09)35 (0.91)1.19 (0.76 to 1.85)0.44
  • a Each patient with eGFR decline from the 6-mo value to a level below the designated threshold (30%, 40%, or 50%) was confirmed by a second laboratory test at least 90 d later. The patients with ≥40% decline in eGFR include all patients with ≥30% decline, whereas patients with ≥50% decline included all patients with ≥40% decline and ≥30% decline.

  • b Number of first occurrence of these events (eGFR decline to a level below the designated threshold confirmed at least 90 d later) during the entire follow-up period after 6 months postrandomization; percentage per person-year that experienced the event is in parentheses.